Sotuletinib Explained

Sotuletinib (BLZ945) is an experimental drug in development for the treatment of amyotrophic lateral sclerosis (ALS). It works as a colony-stimulating factor 1 (CSF1) receptor inhibitor.[1] [2] [3]

Notes and References

  1. Pognan . François . Buono . Chiara . Couttet . Philippe . Galarneau . Jean-René . Timsit . Yoav . Wolf . Armin . Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib . Current Research in Toxicology . 29 October 2022 . 3 . 100091 . 10.1016/j.crtox.2022.100091 . 2666-027X. free . 36353522 . 9637862 .
  2. Thongchot . Suyanee . Duangkaew . Supani . Yotchai . Wasan . Maungsomboon . Sorranart . Phimolsarnti . Rapin . Asavamongkolkul . Apichat . Thuwajit . Peti . Thuwajit . Chanitra . Chandhanayingyong . Chandhanarat . Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis . Human Cell . 2 December 2022 . 36 . 1 . 456–467 . 10.1007/s13577-022-00823-0. free . 36456782 . 9813176 .
  3. Martinez-Gonzalez . Loreto . Martinez . Ana . Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis . Expert Opinion on Investigational Drugs . 1 February 2023 . 32 . 2 . 141–160 . 10.1080/13543784.2023.2178416. 36762798 . 10261/308825 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sotuletinib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.